Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients

J M Lopez-Gomez1, E Verde, R Perez-Garcia

  • 1Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. juanmlopez@senefro.org

Insights

Hypertension is common in hemodialysis patients and linked to cardiovascular events. Strict blood pressure control below 150/90 mm Hg and managing factors like left ventricular hypertrophy are crucial for better outcomes.

Area of Science:

  • Nephrology
  • Cardiology
  • Internal Medicine

Background:

  • Cardiovascular events are the leading cause of death in hemodialysis patients.
  • Hypertension is prevalent in this population but its impact on mortality is debated.
  • Left ventricular hypertrophy (LVH) is a significant predictor of mortality in dialysis patients.

Purpose of the Study:

  • To investigate the role of hypertension in cardiovascular mortality among hemodialysis patients.
  • To explore the relationship between hypertension, LVH, and other risk factors.
  • To suggest optimal blood pressure targets and management strategies.

Main Methods:

  • Review of epidemiological studies on hypertension and mortality in hemodialysis.
  • Analysis of factors contributing to LVH in chronic renal failure.
  • Discussion of current evidence regarding blood pressure goals.

Main Results:

  • Discrepancies in studies may stem from inconsistent hypertension definitions and interactions with factors like malnutrition and LVH.
  • Predialysis blood pressure below 150/90 mm Hg is suggested to prevent complications.
  • Hypertension is a primary driver of LVH, alongside anemia, volume overload, and malnutrition.

Conclusions:

  • Strict blood pressure control is essential for hemodialysis patients.
  • Managing factors contributing to LVH, such as anemia and malnutrition, is critical.
  • Angiotensin-converting enzyme (ACE) inhibitors are recommended for blood pressure management.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...